Xu Y, et al. - In metastatic renal cell carcinoma (mRCC) patients treated with tyrosine kinase inhibitors (TKIs), the prognostic value of performance status (PS) was investigated by analyzing studies assessing the association between pretreatment PS and prognosis in mRCC patients receiving TKIs from electronic databases. This meta-analysis comprised a total of 6,780 patients from 19 studies. Outcomes revealed a significant association of a poor PS with poor overall survival and progression-free survival in these mRCC patients.